BioVectra Inc.

12 articles with BioVectra Inc.

• Mallinckrodt Completes Sale of BioVectra Inc. for up to $250 Million

  11/4/2019

  Milestone reinforces Company's ongoing strategic efforts to focus on branded, high-growth biopharmaceuticals by monetizing a non-core business

• H.I.G. Capital Completes Acquisition of BioVectra

  11/4/2019

  Founded in 1970, BioVectra’s core competencies include microbial fermentation, complex chemistry, high potency, and biologics.

• Mallinckrodt Agrees to Sell BioVectra Inc. to H.I.G. Capital for $250 Million

  9/10/2019

  Mallinckrodt plc announced it has entered into a definitive agreement to sell its wholly owned subsidiary BioVectra Inc.

• BioVectra Inc. Announces a $144.6 Million Expansion Project, Including a $37.5 Million Contribution Through the Government of Canada’s Strategic Innovation Fund

  3/12/2019

  Prime Minister Justin Trudeau visits BioVectra to announce Government of Canada investment in Atlantic Canadian CDMO and high-skilled jobs creation in the region

• BioVectra and Keryx Biopharma Enter Agreement for Ferric Citrate Production Expansion

  12/14/2017

  BioVectra today announced a long-term supply agreement with Keryx Biopharma to manufacture Ferric Citrate, the API in Auryxia tablets.

• BioVectra Inc. Named Agent of Reagent Proteins' Products

  6/25/2013

• Questcor Pharmaceuticals, Inc. (Headquarters) Announces Purchase of BioVectra Inc. for $50.7 Million Upfront

  1/3/2013

• BioVectra Inc. Confirms Partnership With Sandoz, Inc. to Market Docetaxel in the U.S.A.

  1/5/2010

• BioVectra Inc. Announces Oncolix Inc. Signs Manufacturing and Investment Agreement

  9/23/2009

• Therapure Biopharma Inc. Announces Collaboration with BioVectra Inc.

  11/4/2008

• Kane Biotech Inc. Retains BioVectra to Manufacture DispersinB(TM)

  3/4/2008

• Helix Biopharma Signs L-DOS47 Manufacturing Agreement With BioVectra DCL

  1/5/2007